A class action lawsuit has been filed against DexCom Inc., alleging that the company made false and misleading statements regarding its glucose monitoring devices, the G6 and G7. According to the complaint, DexCom implemented material design changes to these products without proper authorization from the U.S. Food and Drug Administration, which allegedly reduced their reliability and posed health risks to users. The lawsuit further claims that DexCom overstated the enhancements, reliability, and accuracy of the G7 device, while downplaying the severity of the issues and associated health risks. As a result, investors allege they suffered losses due to the company's actions and are seeking damages for securities fraud.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1120504) on December 23, 2025, and is solely responsible for the information contained therein.